Potential therapeutic use of IL-37: a key suppressor of innate immunity and allergic immune responses mediated by mast cells

Immunologic Research

Volumn 65, Issue 5, 2017, Pages 982-986

  Conti, Pio ^a   Carinci, Francesco ^b   Lessiani, Gianfranco ^c   Spinas, Enrico ^d   Kritas, Spyridon K ^e   Ronconi, Gianpaolo ^f   Caraffa, Alessandro ^g   Theoharides, Theoharis C ^h  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c Villa Serena Hospital   (Italy)

^d UNIVERSITY OF CAGLIARI   (Italy)

^e ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^f FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^g UNIVERSITY OF PERUGIA   (Italy)

^h TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allergy; IL 37; Immune response; Inflammation; Mast cells

Indexed keywords

CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 37; IL37 PROTEIN, HUMAN;

ALLERGIC ASTHMA; ALLERGIC REACTION; ALLERGY; ANAPHYLAXIS; ANTIINFLAMMATORY ACTIVITY; ASTHMA; AUTOIMMUNE DISEASE; BIOLOGICAL ACTIVITY; DENDRITIC CELL; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INFLAMMATORY DISEASE; INNATE IMMUNITY; MAST CELL; MONOCYTE; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; ADAPTIVE IMMUNITY; ANIMAL; HYPERSENSITIVITY; IMMUNOLOGY; METABOLISM; PHYSIOLOGY;

ADAPTIVE IMMUNITY; ANIMALS; CYTOKINES; DENDRITIC CELLS; HUMANS; HYPERSENSITIVITY; IMMUNITY, INNATE; INFLAMMATION; INTERLEUKIN-1; MAST CELLS;

EID: 85026918250     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-017-8938-7     Document Type: Review

References (40)

1. Dinarello CA, Conti P, Mier JW. Effects of human interleukin-1 on natural killer cell activity: is fever a host defense mechanism for tumor killing? Yale J Biol Med. 1986;59(2):97–106.
2. Theoharides TC, Conti P. Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol. 2004;25(5):235–41.
3. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M. Mast cells as “tunable” effector and immunoregulatory cells: recent advances. Annu Rev Immunol. 2005;23:749–86.
4. Theoharides TC, Kempuraj D, Tagen M, Conti P, Kalogeromitros D. Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev. 2007;217:65–78.
5. Caraffa A, Spinas E, Kritas SK, Lessiani G, Ronconi G, Saggini A, et al. Endocrinology of the skin: intradermal neuroimmune network, a new frontier. J Biol Regul Homeost Agents. 2016;30(2):339–43.
6. Theoharides TC, Petra AI, Taracanova A, Panagiotidou S, Conti P. Targeting IL-33 in autoimmunity and inflammation. J Pharmacol Exp Ther. 2015;354(1):24–31.
7. Sismanopoulos N, Delivanis DA, Mavrommati D, Hatziagelaki E, Conti P, Theoharides TC. Do mast cells link obesity and asthma? Allergy. 2013;68(1):8–15.
8. Carinci F, Lessiani G, Spinas E, Kritas SK, Ronconi G, Caraffa A, et al. Mast cell and cancer with special emphasis on IL-37 an anti-inflammatory and inhibitor of innate immunity: new frontiers. J Biol Regul Homeost Agents. 2016;30(4):945–50.
9. Theoharides TC, Donelan JM, Papadopoulou N, Cao J, Kempuraj D, Conti P. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci. 2004;25(11):563–8.
10. Yang L, Ting Y, Shen Y, Wang L, Zhuang Z. 17β-estradiol modulates the viability, phenotype, endocytosis, and inflammatory cytokine expression of RAW264.7 macrophages. Eur J Inflamm. 2016;14:10–7.
11. Petra AI, Panagiotidou S, Stewart JM, Conti P, Theoharides TC. Spectrum of mast cell activation disorders. Expert Rev Clin Immunol. 2014;10(6):729–39.
12. Antczak A, Domańska-Senderowska D, Górski P, Pastuszak-Lewandoska D, Nielepkowicz-Goździńska A, Szewczyk K, et al. Analysis of changes in expression of IL-4/IL-13/STAT6 pathway and correlation with the selected clinical parameters in patients with atopic asthma. Int J Immunopathol Pharmacol. 2016;29(2):195–204.
13. Yan T. Role of anti-inflammatory cytokines in pathogenesis of pediatric mycoplasma pneumoniae pneumonia. J Biol Regul Homeost Agents. 2016;30(2):541–5.
14. Nacaroglu HT, İsgüder R, Bent S, et al. Can neutrophil/lymphocyte ratio be a novel biomarker of inflammation in children with asthma? Eur J Inflamm. 2016;2:109–12.
15. Marinari S, De Iuliis V, Dadorante V, et al. Cytokine modulation in patients with idiopathic pulmonary fibrosis undergoing treatment with steroids, immunosuppressants, and IFN-γ 1b. J Biol Regul Homeost Agents. 2017;31:59–69.
16. Lin J, Pang L, Liu XL, Xing J. Role of vitacamphore in improving central pro-inflammatory cytokines following transient global ischemia. J Biol Regul Homeost Agents. 2016;30(4):1091–8.
17. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity. 2013;39(6):1003–18.
18. Dinarello CA. A clinical perspective of IL-1β as the gatekeeper of inflammation. Eur J Immunol. 2011;41(5):1203–17.
19. Conti P, Al C, Kritas SK. Mast cell: pro-inflammatory or anti-inflammatory? Jekyll and Hyde, the story continues. J Biol Regul Homeost Agents. 2017;31:263–7.
20. Crincoli V, Ballini A, Fatone L, Di Bisceglie MB, Nardi GM, Grassi FR. Cytokine genotype distribution in patients with periodontal disease and rheumatoid arthritis or diabetes mellitus. J Biol Regul Homeost Agents. 2016;30(3):863–6.
21. Lin Q, Li Y, Zhang D, Jin H. Levels of circulating soluble receptor activator of NF-κB and interleukins-1 predicting outcome of locally advanced basal cell carcinoma. Int J Immunopathol Pharmacol. 2016;29(4):784–89.
22. Li S, Neff CP, Barber K, Hong J, Luo Y, Azam T, et al. Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL-1R8. Proc Natl Acad Sci U S A. 2015;112(8):2497–502.
23. Lunding L, Schröder A, Wegmann M. Allergic airway inflammation: unravelling the relationship between IL-37, IL-18Rα and Tir8/SIGIRR. Expert Rev Respir Med. 2015;9(6):739–50.
24. Luo Y, Cai X, Liu S, Wang S, Nold-Petry CA, Nold MF, et al. Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells. Proc Natl Acad Sci U S A. 2014;111(42):15178–83.
25. Cavalli G, Koenders M, Kalabokis V, Kim J, Tan AC, Garlanda C, et al. Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. Rheumatology (Oxford). 2016;55(12):2220–9.
26. Wenzel S. Mechanisms of severe asthma. Clin Exp Allergy. 2003;33(12):1622–8.
27. Caraffa AL, Varvara G, Spinas E, Kritas SK, Lessiani G, Ronconi G, et al. Is vitamin E an anti-allergic compound? J Biol Regul Homeost Agents. 2016;30(1):11–5. Review
28. Canessa C, Iacopelli J, Pecoraro A, et al. Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies. Int J Immunopathol Pharmacol. 2017;30(1):73–82. doi:10.1177/0394632016681577.
29. Kempuraj D, Conti P, Vasiadi M, Alysandratos KD, Tagen M, Kalogeromitros D, et al. IL-32 is increased along with tryptase in lesional psoriatic skin and is up-regulated by substance P in human mast cells. Eur J Dermatol. 2010;20(6):865–7.
30. Palaska I, Gagari E, Theoharides TC. The effects of P. gingivalis and E. coli LPS on the expression of proinflammatory mediators in human mast cells and their relevance to periodontal disease. J Biol Regul Homeost Agents. 2016;30(3):655–64.
31. Conti C, Caraffa A, Kritas SK, Ronconi G, Fulcheri M. Alexithymia and its relationships with inflammatory response mediated by IL-1 family members. J Biol Regul Homeost Agents. 2017;31(1):21–8. Review
32. Eskandari N, Tashrifi F, Bastan R, Andalib A, Yousefi Z, Peachell PT. Cyclic nucleotide phosphodiesterase isoforms in human basophils and mast cells. Int J Immunopathol Pharmacol. 2016;29(4):654–665.
33. Conti P, Shaik-Dasthagirisaheb YB. Mast cell serotonin immunoregulatory effects impacting on neuronal function: implications for neurodegenerative and psychiatric disorders. Neurotox Res. 2015;28(2):147–53.
34. Conti P, Youinou P, Theoharides TC. Modulation of autoimmunity by the latest interleukins (with special emphasis on IL-32). Autoimmun Rev. 2007;6(3):131–7.
35. Xia T, Zheng XF, Qian BH, Fang H, Wang JJ, Zhang LL, et al. Plasma interleukin-37 is elevated in patients with rheumatoid arthritis: its correlation with disease activity and Th1/Th2/Th17-related cytokines. Dis Markers. 2015;2015:795043.
36. Meyer N, Akdis CA. Vascular endothelial growth factor as a key inducer of angiogenesis in the asthmatic airways. Curr Allergy Asthma Rep. 2013;13(1):1–9.
37. Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol. 2010;11(11):1014–22.
38. Coll-Miró M, Francos-Quijorna I, Santos-Nogueira E, Torres-Espin A, Bufler P, Dinarello CA, et al. Beneficial effects of IL-37 after spinal cord injury in mice. Proc Natl Acad Sci U S A. 2016;113(5):1411–6.
39. Moretti S, Bozza S, Oikonomou V, Renga G, Casagrande A, Iannitti RG, et al. IL-37 inhibits inflammasome activation and disease severity in murine aspergillosis. PLoS Pathog. 2014;10(11):e1004462.
40. Gour N, Wills-Karp M. IL-4 and IL-13 signaling in allergic airway disease. Cytokine. 2015;75(1):68–78.